S1P receptor modulators for treating multiple sclerosis

Details for Australian Patent Application No. 2007264031 (hide)

Owner Novartis AG

Inventors Hiestand, Peter C.; Schnell, Christian

Agent Davies Collison Cave

Pub. Number AU-B-2007264031

PCT Pub. Number WO2008/000419

Priority 0612721.1 27.06.06 GB

Filing date 25 June 2007

Wipo publication date 3 January 2008

Acceptance publication date 27 January 2011

International Classifications

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

Event Publications

18 December 2008 PCT application entered the National Phase

  PCT publication WO2008/000419 Priority application(s): WO2008/000419

27 January 2011 Application Accepted

  Published as AU-B-2007264031

26 May 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007264033-Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors

2007264030-New method for salt preparation